前7月14个创新药获批上市

Group 1 - In the first seven months of this year, Jiangsu approved 14 innovative drugs for market, surpassing last year's total of 13, accounting for nearly 30% of the 49 innovative drugs approved nationwide [1] - The innovative drugs include treatments for diseases such as tumors, spondyloarthritis, and influenza, with Jiangsu's first "platinum-resistant" ovarian cancer drug being a notable highlight [1] - Jiangsu's pharmaceutical industry is supported by nearly 3,000 high-tech enterprises in the biopharmaceutical sector, leading the nation in the number of companies listed in the top 100 pharmaceutical industrial enterprises by main business revenue for 2024 [2] Group 2 - Jiangsu has established seven national key laboratories in the biopharmaceutical field and has been approved to build the first national technology innovation center in this area, enhancing its innovation capabilities [2] - Jiangsu Hengrui Medicine Co., Ltd. has submitted two innovative drugs for approval, providing new treatment options for patients with active ankylosing spondylitis and recurrent or metastatic cervical cancer [2] - The company has increased its R&D investment, which accounted for 29.4% of its sales revenue last year, with a cumulative R&D investment of 46 billion yuan and over 90 self-innovated products in clinical development [2] Group 3 - Suzhou MediPharma Co., Ltd. has submitted an innovative drug that is the first biopharmaceutical product in Jiangsu to adopt a segmented production model, optimizing resource allocation and enhancing collaboration across the industry chain [3] - The segmented production model allows for different stages of production to be carried out in separate locations, improving specialization and efficiency in drug manufacturing [3] - The provincial drug regulatory authority has provided guidance to support the establishment of quality systems and risk management for this innovative production approach [3]